Oculomotor myasthenia gravis refers to oculomotor myasthenia gravis that manifests as symmetrical or asymmetrical ptosis and/or diplopia.
Myasthenia gravis is an acquired autoimmune disease primarily associated with autoantibody-mediated damage to postsynaptic membrane acetylcholine receptors. Skeletal muscles throughout the body can be involved, characterized by fluctuating weakness and easy fatigability, with symptoms that are mild in the morning and severe in the evening, aggravated by activity and relieved by rest.
Ocular myasthenia gravis is the least severe form of myasthenia gravis, accounting for 15% to 20% of patients with severe myasthenia gravis. The lesions are limited to the extraocular muscles, with ptosis and diplopia, and can be bilateral or unilateral.
Patients with myasthenia gravis often have a combination of hyperthyroidism, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases such as pemphigus.
Those diagnosed with myasthenia gravis should be treated with standardized medication under the guidance of a physician and avoid the use of drugs that induce myasthenia gravis.